Initial treatment of nontransplant patients with multiple myeloma

Seminars in Oncology

Volumn 40, Issue 5, 2013, Pages 577-584

  Cerrato, Chiara ^a   Palumbo, Antonio ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CONSTIPATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; EVENT FREE SURVIVAL; EVIDENCE BASED MEDICINE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GERIATRIC DISORDER; HEALTH CARE QUALITY; HERPES ZOSTER; HUMAN; INFECTION; LOW DRUG DOSE; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REDUCED INTENSITY CONDITIONING; SENSORY NEUROPATHY; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CLINICAL TRIALS AS TOPIC; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; PYRAZINES; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84886939600     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2013.07.003     Document Type: Article

References (48)

1. R.A. Kyle, and S.V. Rajkumar Multiple myeloma Blood 111 6 2008 2962 2972
2. R.A. Kyle, F. Buadi, and S.V. Rajkumar Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) Oncology (Williston Park) 25 7 2011 578 586
3. S.V. Rajkumar, A. Dispenzieri, and R.A. Kyle Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment Mayo Clin Proc 81 5 2006 693 703
4. R.A. Kyle, and S.V. Rajkumar Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma Leukemia 23 1 2009 3 9
5. R.A. Kyle, E.D. Remstein, and T.M. Therneau Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma N Engl J Med 356 25 2007 2582 2590
6. G. Csako Immunofixation electrophoresis for identification of proteins and specific antibodies Methods Mol Biol 869 2012 147 171
7. A. Dispenzieri, R. Kyle, and G. Merlini International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders Leukemia 23 2 2009 215 224
8. S.V. Rajkumar Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management Am J Hematol 88 3 2013 225 235
9. R.A. Kyle, B.G.M. Durie, and S.V. Rajkumar Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management Leukemia 24 6 2010 1121 1127
10. C. Jakob, J. Sterz, and P. Liebisch Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma Leukemia 22 9 2008 1767 1772
11. C.L.H. Snozek, J.A. Katzmann, and R.A. Kyle Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system Leukemia 22 10 2008 1933 1937
12. R. Fonseca, B. Barlogie, and R. Bataille Genetics and cytogenetics of multiple myeloma: a workshop report Cancer Res 64 4 2004 1546 1558
13. G.W. Dewald, T. Therneau, and D. Larson Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma Blood 106 10 2005 3553 3558
14. J. Ferlay, H.-R. Shin, F. Bray, D. Forman, C. Mathers, and D.M. Parkin Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer 127 12 2010 2893 2917
15. Karnofsky D, Burchenal J. The clinical evaluation of chemotherapeutic agents in cancer. In MacLeod CM, editor. Evaluation of chemotherapeutic agents. New York: Columbia University Press; 1949:196
16. M.E. Charlson, P. Pompei, K.L. Ales, and C.R. MacKenzie A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 5 1987 373 383
17. Myeloma Trialists' Collaborative Group Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group J Clin Oncol 16 12 1998 3832 3842
18. S. Singhal, J. Mehta, and R. Desikan Antitumor activity of thalidomide in refractory multiple myeloma N Engl J Med 341 21 1999 1565 1571
19. S.K. Kumar, S.V. Rajkumar, and A. Dispenzieri Improved survival in multiple myeloma and the impact of novel therapies Blood 111 5 2008 2516 2520
20. H. Brenner, A. Gondos, and D. Pulte Recent major improvement in long-term survival of younger patients with multiple myeloma Blood 111 5 2008 2521 2526
21. B.G.M. Durie, J.-L. Harousseau, and J.S. Miguel International uniform response criteria for multiple myeloma Leukemia 20 9 2006 1467 1473
22. F. Gay, A. Larocca, and P. Wijermans Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients Blood 117 11 2011 3025 3031
23. T. Facon, J.Y. Mary, and C. Hulin Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial Lancet 370 9594 2007 1209 1218
24. C. Hulin, T. Facon, and P. Rodon Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial J Clin Oncol 27 22 2009 3664 3670
25. A. Waage, P. Gimsing, and P. Fayers Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma Blood 116 9 2010 1405 1412
26. P. Wijermans, M. Schaafsma, and F. Termorshuizen Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 study J Clin Oncol 28 19 2010 3160 3166
27. A. Palumbo, S. Bringhen, and A.M. Liberati Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial Blood 112 8 2008 3107 3114
28. G.J. Morgan, F.E. Davies, and W.M. Gregory Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results Haematologica 97 3 2012 442 450
29. J.F. San Miguel, R. Schlag, and N.K. Khuageva Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma N Engl J Med 359 9 2008 906 917
30. M.-V. Mateos, P.G. Richardson, and R. Schlag Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial J Clin Oncol 28 13 2010 2259 2266
31. M.-V. Mateos, A. Oriol, and J. Martínez-López Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial Lancet Oncol 11 10 2010 934 941
32. A. Palumbo, S. Bringhen, and D. Rossi Bortezomib-melphalan-prednisone- thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial J Clin Oncol 28 34 2010 5101 5109
33. Palumbo A, Bringhen S, Rossi D, Cavalli M, Ria R, Gentilini S. Overall survival benefit for bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide (VMPT-VT) versus bortezomib-melphalan- prednisone (VMP) in newly diagnosed multiple myeloma patients. Blood (ASH Annual Meeting Abstracts); 2012;120:200.
34. S. Bringhen, A. Larocca, and D. Rossi Efficacy and safety of once-weekly bortezomib in multiple myeloma patients Blood 116 23 2010 4745 4753
35. J.A. Zonder, J. Crowley, and M.A. Hussein Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232) Blood 116 26 2010 5838 5841
36. S.V. Rajkumar, S. Jacobus, and N.S. Callander Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial Lancet Oncol 11 1 2010 29 37
37. A. Palumbo, R. Hajek, and M. Delforge Continuous lenalidomide treatment for newly diagnosed multiple myeloma N Engl J Med 366 19 2012 1759 1769
38. A. Palumbo, S. Bringhen, and M.T. Petrucci Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial Blood 104 10 2004 3052 3057
39. A. Palumbo, and K. Anderson Multiple myeloma N Engl J Med 364 11 2011 1046 1060
40. Remission maintenance therapy for multiple myeloma. Arch Intern Med. 1975;135(1):147-52.
41. A. Belch, W. Shelley, and D. Bergsagel A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients Br J Cancer 57 1 1988 94 99
42. A. Palumbo, S. Bringhen, and T. Caravita Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial Lancet 367 9513 2006 825 831
43. H. Ludwig, Z. Adam, and E. Tóthová Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma Haematologica 95 9 2010 1548 1554
44. G.J. Morgan, W.M. Gregory, and F.E. Davies The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis Blood 119 1 2012 7 15
45. M. Attal, J.-L. Harousseau, and S. Leyvraz Maintenance therapy with thalidomide improves survival in patients with multiple myeloma Blood 108 10 2006 3289 3294
46. A. Palumbo, F. Gay, and P. Falco Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation- maintenance in untreated multiple myeloma patients J Clin Oncol 28 5 2010 800 807
47. M.-V. Mateos, A. Oriol, and J. Martínez-López Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial Blood 120 13 2012 2581 2588
48. R. Niesvizky, I.W. Flinn, and R.M. Rifkin Phase 3b UPFRONT study: safety and efficacy of weekly bortezomib maintenance therapy after bortezomib-based induction regimens in elderly, newly diagnosed multiple myeloma patients Blood (ASH Annual Meeting Abstracts) 116 2010 3026